{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:38:18Z","timestamp":1792802298084,"version":"4.5.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82474682"],"award-info":[{"award-number":["82474682"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences","award":["CI2023C063YLL"],"award-info":[{"award-number":["CI2023C063YLL"]}],"id":[{"id":"https:\/\/ror.org\/042pgcv68","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012149","name":"National Key Scientific Instrument and Equipment Development Projects of China","doi-asserted-by":"publisher","award":["2017ZX09301059"],"award-info":[{"award-number":["2017ZX09301059"]}],"id":[{"id":"10.13039\/501100012149","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Open Research Fund of Chengdu University of Traditional Chinese Medicine Key Laboratory of Systematic Research of Distinctive Chinese Medicine Resources in Southwest China","id":[{"id":"https:\/\/ror.org\/00pcrz470","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although filgotinib, a selective Janus kinase 1 inhibitor, has been increasingly applied in the treatment of inflammatory diseases, its comprehensive safety profile remains insufficiently characterized. Using data from the FAERS database covering Q1 2014 to Q2 2024, this study attempts to analyze adverse event signals linked to filgotinib and provide guidance for the safe and sensible clinical usage of filgotinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From Q1 2014 to Q2 2024, information on adverse drug events (ADEs) associated with filgotinib was gathered. The reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) were among the signal detection methods that were employed for analysis following data normalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Filgotinib was shown to be the main suspected medication in ADE reports, exposing 103 preferred terms (PTs) in 17 system organ classes (SOCs). Infections, gastrointestinal disorders, and musculoskeletal and connective tissue disorders were the most commonly reported adverse effects. Additionally, atrial fibrillation, alopecia, elevated serum creatinine, blood creatinine increased, pulmonary embolism, epididymitis, respiratory failure, and osteopenia were identified as potential disproportionate reporting signals for filgotinib, although these were not listed in the official drug label. Notable significant signals included large intestine erosion (ROR 2186.05, 95%CI\n                      <jats:sub>(ROR)<\/jats:sub>\n                      : 1015.94\u20134703.86, PRR 2176.18, 95%CI\n                      <jats:sub>(PRR)<\/jats:sub>\n                      : 1014.64\u20134667.42), mesenteric arterial occlusion (ROR 1832.17, 95%CI\n                      <jats:sub>(ROR)<\/jats:sub>\n                      : 897.68\u20133739.48, PRR 1822.71, 95%CI\n                      <jats:sub>(PRR)<\/jats:sub>\n                      : 896.17\u20133707.20), repetitive strain injury (ROR 1149.27, 95%CI\n                      <jats:sub>(ROR)<\/jats:sub>\n                      : 363.16\u20133637.01, PRR 1147.05, 95%CI\n                      <jats:sub>(PRR)<\/jats:sub>\n                      : 363.24\u20133622.15), oligoarthritis (ROR 755.02, 95%CI\n                      <jats:sub>(ROR)<\/jats:sub>\n                      : 310.74\u20131834.54, PRR 752.59, 95%CI\n                      <jats:sub>(PRR)<\/jats:sub>\n                      : 310.60\u20131823.51), and periostitis (ROR 676.03, 95%CI\n                      <jats:sub>(ROR)<\/jats:sub>\n                      : 319.36\u20131431.06, PRR 672.98, 95%CI\n                      <jats:sub>(PRR)<\/jats:sub>\n                      : 318.97\u20131419.87). The subgroup analysis identified obvious sex and age-specific trends in filgotinib-related adverse reactions, emphasizing a higher risk of renal disorders in females, a preponderance of gastrointestinal events in males, and age-dependent trends involving mesenteric occlusion, increased serum creatinine, and immunoglobulin reduction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While filgotinib demonstrates therapeutic efficacy, it is associated with a range of potential adverse events, underscoring the need for vigilant clinical monitoring. Particular attention should be given to gastrointestinal, cardiovascular, respiratory, and metabolic complications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0338188","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:27:50Z","timestamp":1765823270000},"page":"e0338188","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib"],"prefix":"10.1371","volume":"20","author":[{"given":"Yinli","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0975-9251","authenticated-orcid":true,"given":"Zhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"11","key":"pone.0338188.ref001","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1093\/rheumatology\/kez184","article-title":"Symptoms associated with inflammatory arthritis are common in the primary care population: results from the joint symptoms survey","volume":"58","author":"SL Hider","year":"2019","journal-title":"Rheumatology"},{"issue":"1","key":"pone.0338188.ref002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-020-2115-4","article-title":"Innate lymphoid cells in inflammatory arthritis","volume":"22","author":"W Fang","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"pone.0338188.ref003","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3390\/cells10113000","article-title":"Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis","volume":"10","author":"M Iwaszko","year":"2021","journal-title":"Cells"},{"issue":"1","key":"pone.0338188.ref004","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"C Xue","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"pone.0338188.ref005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"BN Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"pone.0338188.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212595","article-title":"Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis","volume":"8","author":"M Biggioggero","year":"2019","journal-title":"Drug Context"},{"issue":"6","key":"pone.0338188.ref007","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","article-title":"Filgotinib: A Clinical Pharmacology Review","volume":"61","author":"F Namour","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"pone.0338188.ref008","article-title":"Efficacy and Safety of Tofacitinib in the Management of Ankylosing Spondylitis: A Comprehensive Systematic Review","volume":"17","author":"M Burhanuddin","year":"2025","journal-title":"Cureus"},{"key":"pone.0338188.ref009","doi-asserted-by":"crossref","first-page":"1586792","DOI":"10.3389\/fimmu.2025.1586792","article-title":"Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"16","author":"R Chai","year":"2025","journal-title":"Front Immunol"},{"issue":"11","key":"pone.0338188.ref010","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1093\/rheumatology\/keaf356","article-title":"The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors: a review of the literature","volume":"64","author":"D Nagra","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"10162","key":"pone.0338188.ref011","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"D van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"pone.0338188.ref012","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"PG Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"pone.0338188.ref013","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005033","article-title":"Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes","volume":"11","author":"X Mariette","year":"2025","journal-title":"RMD Open"},{"issue":"18","key":"pone.0338188.ref014","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-020-01439-0","article-title":"Filgotinib: First Approval","volume":"80","author":"S Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"10292","key":"pone.0338188.ref015","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"BG Feagan","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"pone.0338188.ref016","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"B Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"pone.0338188.ref017","first-page":"391","article-title":"Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis","volume":"163","author":"C Martinez-Molina","year":"2024","journal-title":"Med Clin (Barc)"},{"issue":"3","key":"pone.0338188.ref018","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/cpt.3139","article-title":"Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database","volume":"115","author":"D Li","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"pone.0338188.ref019","article-title":"Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"RJ Yu","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"pone.0338188.ref020","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)","volume":"1","author":"K Anand","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"1","key":"pone.0338188.ref021","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40360-023-00702-w","article-title":"A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)","volume":"24","author":"S Zou","year":"2023","journal-title":"BMC Pharmacol Toxicol"},{"key":"pone.0338188.ref022","doi-asserted-by":"crossref","first-page":"1280490","DOI":"10.3389\/fphar.2023.1280490","article-title":"A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system","volume":"14","author":"H Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"pone.0338188.ref023","doi-asserted-by":"crossref","first-page":"1251961","DOI":"10.3389\/fphar.2024.1251961","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor","volume":"15","author":"Y Pan","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"pone.0338188.ref024","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003880","article-title":"Metabolic and molecular imaging in inflammatory arthritis","volume":"10","author":"R Noversa de Sousa","year":"2024","journal-title":"RMD Open"},{"issue":"2","key":"pone.0338188.ref025","article-title":"Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondyloarthritis) and gastrointestinal or liver comorbidity","volume":"2012","author":"H Radner","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"pone.0338188.ref026","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1872312810666151223103353","article-title":"Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions","volume":"10","author":"F Namour","year":"2016","journal-title":"Drug Metab Lett"},{"key":"pone.0338188.ref027","article-title":"Global epidemiology of rheumatoid arthritis","author":"A Finckh","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"10089","key":"pone.0338188.ref028","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"J Sieper","year":"2017","journal-title":"Lancet"},{"issue":"10114","key":"pone.0338188.ref029","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"SC Ng","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"pone.0338188.ref030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/s10165-008-0026-3","article-title":"Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2)","volume":"18","author":"Y Tanaka","year":"2008","journal-title":"Mod Rheumatol"},{"issue":"1","key":"pone.0338188.ref031","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41598-023-50379-8","article-title":"Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study","volume":"14","author":"C Martinez-Molina","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"pone.0338188.ref032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial","volume":"322","author":"MC Genovese","year":"2019","journal-title":"JAMA"},{"issue":"5","key":"pone.0338188.ref033","first-page":"1043","article-title":"Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry","volume":"42","author":"M Fornaro","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"pone.0338188.ref034","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/1756-185X.12998","article-title":"The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study","volume":"20","author":"E Kato","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"pone.0338188.ref035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/mr\/roac081","article-title":"Age and symptoms at onset of ankylosing spondylitis in Japanese patients","volume":"33","author":"K Kishimoto","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"28","key":"pone.0338188.ref036","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.3748\/wjg.v20.i28.9458","article-title":"Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis","volume":"20","author":"BC da Silva","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"1","key":"pone.0338188.ref037","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12876-020-01296-x","article-title":"Elderly-onset vs adult-onset ulcerative colitis: a different natural history?","volume":"20","author":"I Zammarchi","year":"2020","journal-title":"BMC Gastroenterol"},{"issue":"12","key":"pone.0338188.ref038","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1111\/bcp.13726","article-title":"Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor","volume":"84","author":"F Namour","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"pone.0338188.ref039","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ecco-jcc\/jjab206","article-title":"Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis","volume":"16","author":"F D\u2019Amico","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"18","key":"pone.0338188.ref040","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1080\/14656566.2021.1967929","article-title":"Evaluating filgotinib for the treatment of rheumatoid arthritis","volume":"22","author":"C Richez","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"pone.0338188.ref041","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"B Clarke","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"pone.0338188.ref042","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","article-title":"JAK inhibitors for rheumatoid arthritis","volume":"32","author":"S Kubo","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"pone.0338188.ref043","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s40744-023-00599-1","article-title":"Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis","volume":"10","author":"A Balsa","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"6","key":"pone.0338188.ref044","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis","volume":"158","author":"PA Olivera","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"pone.0338188.ref045","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"R Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pone.0338188.ref046","doi-asserted-by":"crossref","unstructured":"Genovese MC, Winthrop K, Tanaka Y, et al. Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from 7 clinical trials. In: 21st Annual Congress of the European League Against Rheumatism. 2020. Available from: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S000349672467130X","DOI":"10.1136\/annrheumdis-2020-eular.267"},{"issue":"2","key":"pone.0338188.ref047","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"KL Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"pone.0338188.ref048","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/ard-2023-224017","article-title":"Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies","volume":"82","author":"W Reinisch","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"pone.0338188.ref049","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1007\/s12325-022-02168-4","article-title":"MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases","volume":"39","author":"WJG Hellstrom","year":"2022","journal-title":"Adv Ther"},{"key":"pone.0338188.ref050","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa896","article-title":"JAK1 inhibition and inflammatory bowel disease","volume":"60","author":"C Harris","year":"2021","journal-title":"Rheumatology (Oxford)"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:28:01Z","timestamp":1765823281000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338188"}},"subtitle":[],"editor":[{"given":"Amirreza","family":"Khalaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0338188","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}